Seelos' stock plunges by over 75% af­ter ke­t­a­mine drug for sui­cide pre­ven­tion fails a PhII tri­al

See­los Ther­a­peu­tics’ in­tranasal racemic ke­t­a­mine can­di­date has missed the pri­ma­ry end­point in a Phase II tri­al of ma­jor de­pres­sive dis­or­der pa­tients with acute sui­ci­dal ideation …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER